Appendix Table C59Trial description: combination nasal selective antihistamine plus intranasal corticosteroid versus intranasal corticosteroid and nasal antihistamine

Author, YearLocation, Site(s)Enrollment/Treatment DurationFunding/Author Industry DisclosuresNInclusion CriteriaExclusion CriteriaaRescue RxObjective DiagnosisRun in PeriodPollen CountPatient BlindingAssessor Blinding
Carr, 2012 (Trial 1)N.America
Multiple
March 2008
2 weeks
Industry
Yes
622Minimum SAR severity and durationSAR meds/-
Other meds
Chronic asthma
Infection
Deformities
No
Carr, 2012 (Trial 2)N.America
Multiple
August 2008
2 weeks
Industry
Yes
576Minimum SAR severity and durationSAR meds/-
Other meds
Chronic asthma
Infection
Deformities
No
Carr, 2012 (Trial 3)N.America
Multiple
April 2009
2 weeks
Industry
Yes
1343Minimum SAR severity and durationSAR meds/-
Other meds
Chronic asthma
Infection
Deformities
No
Hampel, 2010N.America
Multiple
January 2007
2 weeks
Industry
Yes
459Minimum SAR severity and durationSAR meds/-
Other meds
Infection
Deformities
No
Ratner, 2008N.America
Multiple
December 2005
2 weeks
Industry
Yes
151Minimum SAR severity and durationSAR meds/+
Other meds
No

N = patients randomized to comparator groups of interest; SAR = seasonal allergic rhinitis.

a

+, -, or NR indicates whether FDA-recommended washout periods were required (+), were not required (-), or were not reported (NR) for restricted SAR medications prior to trial entry.

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.